The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice
- 1 October 1998
- journal article
- research article
- Published by Oxford University Press (OUP)
- Vol. 74 (876) , 600-601
- https://doi.org/10.1136/pgmj.74.876.600
Abstract
Summary: Treatment with a HMG-CoA reductase inhibitor (statin) following a myocardial infarction has been shown to reduce the incidence of subsequent coronary revascularisation, myocardial infarction and cardiovascular death. The majority (89%) of patients admitted to the coronary care unit of our hospital received a fasting cholesterol check as part of a routine coronary care unit protocol. However, our survey shows that only 26% of patients surviving an acute myocardial infarction were on treatment with a statin at follow-up. Furthermore, those receiving statins were given smaller doses than those used in clinical trials. One way to ensure patients receive adequate treatment with statins, may be to include it as part of a coronary care unit protocol.Keywords
This publication has 4 references indexed in Scilit:
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Hyperlipidemia and Coronary DiseaseCirculation, 1995
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.Circulation, 1994